概要
Click Here to View the Preriminaly Program (Japanese, English)
Click Here to View the JAM2022 site
In 2022, DIA events are returning to a face-to-face format. DIA is committed to delivering a safe and secure conference to all participants. This means, for this event all in-person participants must comply with our Event Safety Code of Conduct, which requires either vaccination, certificate of recovery, or proof of inability to be vaccinated alongside a valid PCR test. Please click here for more information regarding our Event Safety Code of conduct.
The theme of the 19th DIA Japan Annual Meeting is “New "Quest for the future"- Moving Creativity and Innovation Forward in "New Normal" - ”. This means that we who have experienced COVID 19 will explore the future in a new normal environment. COVID19 has brought us lives and environments that we have never experienced before. While face-to-face work declined dramatically, digital transformation accelerated at once. They also promoted extremely rapid development of vaccines and therapeutic agents, as well as new clinical trial models including telemedicine. In addition, the importance of self-care associated with refraining from visiting medical institutions and the importance of addressing the issue of infodemics were reaffirmed.
In the new normal environment that has brought about by COVID19, we are seeking to implement new clinical trials, implement safety measures, disseminate information, develop new modalities, and respond to self-care. There is a need for new Creativity and Innovation on pharmaceuticals, medical devices, regenerative medicine, and other products for the future. We wish to share and discuss how to proceed with this in advance, as well as the efforts, experiences and ideas of you, and to make it a conference to proceed further in advance. It is hoped that discussions will take place from a variety of positions and perspectives.
This year, we will hold the meeting in a hybrid format (In-person and Live Virtual) considering the status of expansion of new coronavirus infectious diseases. The following two types of lecture are planned.
- Live lectures: Live (partially recorded) speaks (and live panel discussions) on the day and date of each session. In principle, a live video of the day is recorded and can be viewed until the end of November.
- On-demand lectures: Prerecorded lectures (and panel discussions) are distributed. Recordings can be viewed from the first day of the annual meeting until the end of November.
We sincerely look forward to your participation.
プログラム委員会
-
Tomiko Tawaragi • Chief Director
RAD-AR, Japan -
Kazuhiko Ishida, MSc, RPh • Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Naoki Isogawa, PhD • Deputy head of SSI East Asia
UCB Japan, Japan -
Keiko Katsui, PhD • Deputy Director / AMED Program Officer, Divison of Research Integrity, Social Co
Japan Agency for Medical Research and Development (AMED), Japan -
Kana Maruyama • Manager, Labeling Group, Regulatory Maintenance Department, RA Division
Janssen Pharmaceutical K.K., Japan -
Sho Mizokawa • Manager, Development Project Management, Development,
Astellas Pharma Inc., Japan -
Takashi Moriya, PhD, MBA • Product Owner (Senior Manager) - Healthcare
Woven Alpha, Inc. (Woven Planet Holdings, Inc. group company), Japan -
Hiroyuki Murakami • Duputy Review Director, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Noriaki Nagao, MPharm, PMP • Clinical Development Dept. Pharmaceutical Division
Japan Tobacco Inc., Japan -
Atsuo Nakagawa, MD, PhD • Assistant Professor, The Center for Clinical Research
Keio University School of Medicine, Japan -
Yukiko Nishimura, PhD, MSc • President
NPO ASrid, Japan -
Katsuhiko Sawada, MPharm • Director, Research and Development Dept.
Otsuka Medical Devices Co.Ltd., Japan -
Yasuharu Shibata, MSc • Head of Clinical Data Management, Cliinical Data Management
MSD K.K., Japan -
Kazumi Sunamura • Director, Regulatory Strategy & Policy 2
Pfizer R&D Japan, Japan -
Kazuyuki Suzuki, MSc • Oncology Trial Management Group, Trial Management Department, Japan Development
Novartis Pharma K.K., Japan -
Keiko Tsumori, MSc • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Tetsuya Watanabe, RPh • Senior Medical Director, Medical Affairs
Astellas Pharma Inc., Japan -
Miyoko Yamauchi • Clinical Leader, Specialty Clinical Development Dept.
Chugai Pharmaceutical Co.Ltd. , Japan -
Haruko Yamamoto, MD, PhD • Chief Medical Officer, Associate Executive Director
Pharmaceutical and Medical Devices Agency, Japan -
Junichi Nishino, MSc, RPh • Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Goshi Ozawa, MS • CEO & President
Real Discovery Outdoors Co,. Ltd., Japan -
Rie Matsui, RPh • Senior Director, Regional Labeling Head for APAC
Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Shinichi Nishiuma, MD • Head of Oncology Medical Science, Japan medical
BMS, Japan -
Sonoko Misawa, MD, PhD • Associate Professor
Chiba University, Japan -
Mika Ogasawara • Data Quality Lead, Biometrics and Data Management
Pfizer R&D Japan G.K., Japan -
Taro Amagasaki, PhD • Head, Analytics Japan
Novartis Pharma K.K., Japan -
Yukihiro Matsuda, MSc • Project Manager, Project Leadership
PRA Health Sciences K.K., Japan -
Mitsuo Ishikawa, MPharm • Home Healthcare New Business Planning Department
Teijin Pharma Limited, Japan -
Mengyan Deng • Senior Associate, Japan Regulatory Affairs
Eisai Co., Ltd., Japan -
Koichi GOTO • Deputy Manager
CM Plus Corporation, Japan -
Nanako Hamazaki • Tsukuba Clinical Research & Development Organization
University of Tsukuba, Japan -
Yuta Kasai • Japan-Asia Clinical Development 2
Astellas Pharma Inc, Japan -
Tomoki Kato, MS • Associate Manager, Clinical Quality Management Group, R&D Division
Daiichi Sankyo Company, Limited, Japan -
Fumitaka Kawasaki • Clinical Affairs, Senior Specialist
Edwards Lifesciences Limited, Japan -
Tomoko Kondo, PhD, RPh • Associare Professor
Joint Research Center for Human Retrovirus Infection, Japan -
Akiko Nishioka • Clinical Research Associate, Clinical Operation
Novartis Pharma K.K., Japan -
Tetsuya Sasaki, PhD • Chief of International Trial Management Section, Research Management Division,
National Cancer Center Hospital, Japan -
Chiaki Takeuchi • Japan Development Operations Clinical Site Management Group
Abbvie GK, Japan -
Yuji Utsuno • Reviewer, Advanced Review with Electronic Data Promotion Group
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yusaku Yoshioka • Office of Review Manegement Division of Innovation Support and Pharmaceutical Af
Pharmaceuticals and Medical Devices Agency (PMDA), Japan